Publications

Search our bibliography using the filters on the right-hand side.

Displaying 401 through 450 of 713 publications.

Wilkins E, Fisher M, Brogan AJ, Talbird SE. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naive adults with HIV-1 infection in the United Kingdom. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014. [abstract] Value Health. 2014 May; 17(3):A276.

Parikh R, Taychakhoonavudh S, White C, Franzini L. Sources of spending variation in professional services among Texas Hospital Referral Regions: an analysis of private insurance population. Poster presented at the 2011 ISPOR 16th Annual International Meeting; May 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3):A18. doi: 10.1016/j.jval.2014.03.116

Hauber AB, Nguyen H, Posner JD, Ervin CM, LaRue S, Kalsekar I. Patient preferences for frequency of glucagon-like peptide-1 receptor agonist (glp-1ra) injections in the treatment of type 2 diabetes. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014. [abstract] Value Health. 2014 May; 17(3):A255.

Schwab PE, Saundankar V, Bouchard J, Moretz C, Baltz J. Delayed treatment modifications for patients with type 2 diabetes mellitus with very poor glycemic control. Poster presented at the 2014 ISPOR 19th Annual International Meeting; May 31, 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3).

Ramamohan V, Mladsi DM, Kaye JA, Boey W, Pozzi R. An outcomes model for high-risk non-muscle-invasive bladder cancer treatment options. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 2, 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3):A87.

Purser MF, Wilson MR, Mladsi DM, Wu Y. Literature review of economic models for the treatment of parkinson's disease. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 2, 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3):A60. doi: 10.1016/j.jval.2014.03.355

Lewis S, Price M, Dwyer KA, O'Brien S, Heekin RD, Yates PJ, Beverland D, Mordin M. Development of a scale to assess performance following primary total knee arthroplasty. Value Health. 2014 Apr 21;17(4):350-9. doi: 10.1016/j.jval.2014.01.006

Forns J, Vegas O, Julvez J, Garcia-Esteban R, Rivera M, Lertxundi N, Guxens M, Fano E, Ferrer M, Grellier J, Ibarluzea J, Sunyer J. Association between child cortisol levels in saliva and neuropsychological development during the second year of life. Stress Health. 2014 Apr;30(2):142-8. doi: 10.1002/smi.2504

Lairson DR, Parikh RC, Cormier JN, Du XL. Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer. Value Health. 2014 Feb;17(1):34-42.

DeMuro C, Clark M, Doward L, Evans E, Mordin M, Gnanasakthy A. Assessment of PRO label claims granted by the FDA as compared to the EMA (2006–2010). Value Health. 2013 Dec;16(8):1150-5. doi: 10.1016/j.jval.2013.08.2293

von Scheele B, Mauskopf J, Brodtkorb T, Ainsworth C, Galani Berardo C, Patel A. Relationship between modelling approach and reported outcomes: case studies of models for the treatment of schizophrenia. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A589.

Wolowacz S, Brockbank J, Sunderland TJ, Gonschior AK. Cost-effectiveness of dabigatran etexilate for the secondary prevention of recurrent deep vein thrombosis and pulmonary embolism in the United Kingdom. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A526.

Stull DE, Mcbride D, Gnanasakthy A, Balp M. Correlations between changes in the urticaria activity score (UAS7) and the dermatology life quality index (DLQI) from baseline to 28 or 40 weeks: comparisons of trajectories of change in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU). Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A509.

Woods MS, Kiri S, Ling CS, McCrink L, Zimovetz E, Hass B. A systematic review of economic evidence in hepatitis c: methods used in recent economic evaluations. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A579.

Woods MS, Kiri S, Ling CS, McCrink L, Zimovetz E, Hass B. A systematic review of economic evidence in hepatitis c: an overview of cost, utility, and cost-effectiveness data. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A349.

Wilburn J, McKenna S, Twiss J, Kemp K, Campbell S. Validation of the Crohn's Life Impact Questionnaire (CLIQ), the first patient-reported outcome measure specific to adults with Crohn's disease. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A499-500. doi: 10.1016/j.jval.2013.08.1129

Wilburn J, McKenna S, Twiss J, Kemp K, Campbell S. Validating the Unidimensional Fatigue Impact Scale (U-FIS) for use in Crohn's disease. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A499. doi: 10.1016/j.jval.2013.08.1128

Ainsworth C, Kiri S, Ling CS, Heyes AE, Hass B. The global burden, incidence, and prevalence of chronic hepatitis c. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A342.

Davis KL, Candrilli S. Recent trends in hospital costs, length of stay, and mortality associated with pediatric meningococcal disease in the United States. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A349.

Davis KL, Candrilli S. Recent trends in incidence and demographics of pediatric meningococcal disease in the United States. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A342.

Twiss J, McKenna S, Graham JE, Swetz KM, Sloan J, Gomberg-Matiland M. Assessing measurement equivalence of different forms of administration of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) using Rasch analysis. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A606. doi: 10.1016/j.jval.2013.08.1731

Twiss J, McKenna S, Rouse M. Using Rasch analysis to co-calibrate scores from outcome measures specific to asthma (ALIS), chronic obstructive pulmonary disease (LCOPD) and pulmonary hypertension (CAMPHOR). Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A605. doi: 10.1016/j.jval.2013.08.1724

Hogue S, Scott A, van Amerongen D, Hollis K, McLeod L, Brogan A. Payer and decision maker use of observational studies for health care reimbursement decisions. Poster presented at the 2013 ISPOR 18th Annual International Meeting; April 30, 2013. [abstract] Value Health. 2013 Nov; 16(7):A459-60.

Bhattacharyya S, Sacco P, Shirore R, Sonathi V, Thomas SK. A de novo economic model to assess the cost and quality of life consequences of an intervention for levodopa induced dyskinesia amongst patients with Parkinson's disease. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A590-1.

Ling CS, Weisgerber-Kriegl U, Njue AI, Heyes A, Kaye J. The effect of positive margins on outcomes in breast cancer. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A394.

Rycroft C, Fernandez M, Copley-Merriman K. Systematic literature reviews at the heart of health technology assessment: a comparison across markets. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A481.

Raspa M, Bishop E, Candrilli S, Mitra D, Sacco P, Petrillo J, Bailey D. US caregiver burden in Fragile X syndrome as a function of a health-state utility index. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A625.

Korsnes JS, Goodwin BB, Candrilli SD. The association between adherence to antiretroviral therapy and economic outcomes among commercially insured and medicaid hiv patients in the United States. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A348-9.

Novick D, Montgomery W, Aguado J, Kadziola Z, Peng X, Brugnoli R. Factors associated with pain persistence in patient with depression during a 3-month follow-up period. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Amsterdam, The Netherlands. [abstract] Value Health. 2013 Nov; 16(7):A544.

Ara R, Basarir H, Keetharuth A, Weatherly H, Barbieri M, Sculpher MJ. Economic evidence of surgical procedures in cancer: a systematic literature review. Poster presented at the 2013 ISPOR 16th Annual European Congress; October 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A411. doi: 10.1017/S0266462314000531

Rouse M, McKenna S, Twiss J, Graham JE, Wilburn J. Quality of life outcomes in multiple sclerosis: a review of the literature. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A626. doi: 10.1016/j.jval.2013.08.1843

Graham JE, McKenna S, Wilburn J, Twiss J. Assessing quality of life in adult growth hormone deficiency: further development of the QoL-AGHDA. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A446-7. doi: 10.1016/j.jval.2013.08.710

Mladsi DM, Ronquest NA, Tannus G, Fonseca M, Saag K. Estimated cost effectiveness of lower-dose submicron diclofenac compared with traditional diclofenac in Brazil. Poster presented at the 2013 ISPOR 4th Latin America Conference; September 2013. Buenos Aires, Argentina. [abstract] Value Health. 2013 Sep; 16(7):PA717-8. doi: 10.1016/j.jval.2013.08.2226

Brogan A, Talbird S, Thompson J, Kim Y, Olson J, Peterson J, Piontkowsky D, Pietrandoni G. Budget impact of the introduction of elvitegravir/cobicistat/emtricitabine/tenofovir, the first integrase inhibitor-based single-tablet antiretroviral regimen for HIV treatment, to US third-party payers. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2, 2013. Dublin, Ireland. [abstract] Value Health. 2013 Aug; 16(7):A343-4.

Mines D, Nickel KB, Wallace AE, Warren DK, Olsen MA. Using claims data for surgical site infection surveillance after herniorrhaphy. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 2013. New Orleans, LA. [abstract] Value Health. 2013 May; 16(3):a79.

Candrilli S, Karve S. Recent trends in type-2 diabetes mellitus–related inpatient care among pediatric patients in the United States. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 1, 2013. [abstract] Value Health. 2013 May; 16(3):A162.

Copley-Merriman K, Olanrewaju B, Hogue S. The temporal relationship between NSAIDS and risk of gastrointestinal, cardiovascular, and renal events: a systematic review. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 2, 2013. [abstract] Value Health. 2013 May; 16(3):A110.

Davis KL, Fitzgerald TP, Meyers J, Kulkarni A, Svarvar P, Hewitt DJ. Economic burden of adverse treatment effects in parkinson's disease: evidence from a large employer population. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 2013. New Orleans, LA. [abstract] Value Health. 2013 May; 16(3):A103-4.

Davis KL, Fitzgerald T, Meyers J, Kulkarni A, Svarvar P, Hewitt D. Incidence of adverse treatment effects in parkinson's disease: evidence from a large employer population. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 15, 2013. [abstract] Value Health. 2013 May; 16(3):A100.

Davis KL, Fitzgerald T, Kulkarni A, Meyers J, Svarvar P, Hewitt D. Comparative risk of adverse treatment effects in parkinson's disease: evidence from a large employer population. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 15, 2013. [abstract] Value Health. 2013 May; 16(3):A100.

Copley-Merriman C, Olanrewaju B, Hogue S. Systematic literature review of the temporal relationship between nsaid use and gastrointestinal, cardiovascular, or renal events. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 2013. New Orleans, LA. [abstract] Value Health. 2013 May; 16(3):A110.

DiBenedetti D, Coles T, Sharma T. Recruiting patients with a rare blood disorder and their caregivers through social media. Poster presented at the 2013 ISPOR 18th Annual International Meeting; April 23, 2013. [abstract] Value Health. 2013 May; 16(3):A51.

DiBenedetti D, Coles T, Ling CS, Sharma T, Pericleous L. Web-based study of patients and caregivers in the United States and Canada: perspectives on improvements in stability of factor viii products for hemophilia a. Poster presented at the 2013 ISPOR 18th Annual International Meeting; April 30, 2013. [abstract] Value Health. 2013 May; 16(3):A121.

Brennan VK, Colosia AD, Copley-Merriman C, Hass B, Palencia R. Systematic literature review of utilities relating to patients with type-2 diabetes mellitus experiencing a stroke or myocardial infarction. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 2013. New Orleans, LA. [abstract] Value Health. 2013 May; 16(3):A168. doi: 10.1016/j.jval.2013.03.841

Brennan VK, Colosia AD, Copley-Merriman C, Hass B, Palencia R. Systematic literature review of costs related to patients with type 2 diabetes mellitus experiencing a stroke or myocardial infarction. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 7, 2013. New Orleans, LA. [abstract] Value Health. 2013 May; 16(3):A162. doi: 10.1016/j.jval.2013.03.811

Odom D, Brogan AJ, Talbird SE, Schenkel B. A network meta-analysis of randomized, controlled trials of ustekinumab and adalimumab for moderate-to-severe psoriasis. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 2013. [abstract] Value Health. 2013 May; 16(3):A112. doi: 10.1016/j.jval.2013.03.532

Xe Y, Bays H, Schwab PE, Louder A. Concomitant statin use with ezetimibe or colesevelam for treatment of hypercholesterolemia. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 18, 2013. New Orleans, LA. [abstract] Value Health. 2013 May; 16(3):A295. doi: 10.1016/j.jval.2013.03.1529

Mordin M, Hogue S, Barrows S, van Amerongen D. Safe and effective versus reasonable and necessary: is the deck stacked against medical devices? Poster presented at the 2013 ISPOR 18th Annual International Meeting; April 30, 2013. [abstract] Value Health. 2013 May; 16(3):246.

Mordin M, Copley-Merriman C, Mauskopf J, Sweeney C, Bhattacharyya S, Farup C, Beach W, Higgins L, McIntyre L. Surgical innovation: do we need a more balanced framework for evidence? Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 3, 2013. [abstract] Value Health. 2013 May; 16(3):A247.

Barrett A, DiBenedetti D, Phatak H, lloeje U. Structured review of patient-reported outcome instruments for assessing atrial fibrillation. Poster presented at the 2013 ISPOR 18th Annual International Meeting; April 23, 2013. [abstract] Value Health. 2013 May; 16(3):A293.